E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis

Molecular Cell

Volumn 54, Issue 6, 2014, Pages 987-998

  Lu, Min ^a   Marsters, Scot ^a   Ye, Xiaofen ^a   Luis, Elizabeth ^a   Gonzalez, Lino ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CASPASE 8; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR; UVOMORULIN;

ACTIN POLYMERIZATION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOSKELETON; EPITHELIAL CANCER CELL LINE; EPITHELIAL MESENCHYMAL TRANSITION; HOMEOSTASIS; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION;

ACTIN CYTOSKELETON; ALPHA CATENIN; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CADHERINS; CALCIUM; CASPASE 8; CELL LINE, TUMOR; CYTOSKELETON; EPITHELIAL-MESENCHYMAL TRANSITION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HEK293 CELLS; HUMANS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903577507     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.04.029     Document Type: Article

References (52)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
2. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 2008, 7:1001-1012.
3. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
4. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J.Clin. Invest. 2008, 118:1979-1990.
5. Austin C.D., Lawrence D.A., Peden A.A., Varfolomeev E.E., Totpal K., De Mazière A.M., Klumperman J., Arnott D., Pham V., Scheller R.H., Ashkenazi A. Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl. Acad. Sci. USA 2006, 103:10283-10288.
6. Cavallaro U., Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 2004, 4:118-132.
7. Chamow S.M., Ashkenazi A. Immunoadhesins: principles and applications. Trends Biotechnol. 1996, 14:52-60.
8. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
9. Dickens L.S., Boyd R.S., Jukes-Jones R., Hughes M.A., Robinson G.L., Fairall L., Schwabe J.W.R., Cain K., Macfarlane M. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol. Cell 2012, 47:291-305.
10. Frisch S.M., Screaton R.A. Anoikis mechanisms. Curr. Opin. Cell Biol. 2001, 13:555-562.
11. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
12. Gross J.C., Schreiner A., Engels K., Starzinski-Powitz A. E-cadherin surface levels in epithelial growth factor-stimulated cells depend on adherens junction protein shrew-1. Mol. Biol. Cell 2009, 20:3598-3607.
13. Grosse-Wilde A., Voloshanenko O., Bailey S.L., Longton G.M., Schaefer U., Csernok A.I., Schütz G., Greiner E.F., Kemp C.J., Walczak H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J.Clin. Invest. 2008, 118:100-110.
14. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002, 7:247-260.
15. Guillot C., Lecuit T. Mechanics of epithelial tissue homeostasis and morphogenesis. Science 2013, 340:1185-1189.
16. Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat. Rev. Mol. Cell Biol. 2005, 6:622-634.
17. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
18. Harris T.J.C., Tepass U. Adherens junctions: from molecules to morphogenesis. Nat. Rev. Mol. Cell Biol. 2010, 11:502-514.
19. Hong S., Troyanovsky R.B., Troyanovsky S.M. Binding to F-actin guides cadherin cluster assembly, stability, and movement. J.Cell Biol. 2013, 201:131-143.
20. Jin Z., Li Y., Pitti R., Lawrence D., Pham V.C., Lill J.R., Ashkenazi A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009, 137:721-735.
21. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
22. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000, 12:611-620.
23. Kleiner S., Faisal A., Nagamine Y. Induction of uPA gene expression by the blockage of E-cadherin via Src- and Shc-dependent Erk signaling. FEBS J. 2007, 274:227-240.
24. Kobielak A., Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat. Rev. Mol. Cell Biol. 2004, 5:614-625.
25. Lu M., Krauss R.S. N-cadherin ligation, but not Sonic hedgehog binding, initiates Cdo-dependent p38alpha/beta MAPK signaling in skeletal myoblasts. Proc. Natl. Acad. Sci. USA 2010, 107:4212-4217.
26. Massagué J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13:616-630.
27. Ouyang W., Yang C., Liu Y., Xiong J., Zhang J., Zhong Y., Zhang G., Zhou F., Zhou Y., Xie C. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells. Int. J. Oncol. 2011, 39:1577-1586.
28. Ratheesh A., Yap A.S. A bigger picture: classical cadherins and the dynamic actin cytoskeleton. Nat. Rev. Mol. Cell Biol. 2012, 13:673-679.
29. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.
30. Schleich K., Warnken U., Fricker N., Oztürk S., Richter P., Kammerer K., Schnölzer M., Krammer P.H., Lavrik I.N. Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model. Mol. Cell 2012, 47:306-319.
31. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
32. Shapiro L., Weis W.I. Structure and biochemistry of cadherins and catenins. Cold Spring Harb. Perspect. Biol. 2009, 1:a003053.
33. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
34. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
35. Singh A., Sweeney M.F., Yu M., Burger A., Greninger P., Benes C., Haber D.A., Settleman J. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 2012, 148:639-650.
36. Song J.H., Tse M.C.L., Bellail A., Phuphanich S., Khuri F., Kneteman N.M., Hao C. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells. Cancer Res. 2007, 67:6946-6955.
37. Soria J.-C., Márk Z., Zatloukal P., Szima B., Albert I., Juhász E., Pujol J.-L., Kozielski J., Baker N., Smethurst D., et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J.Clin. Oncol. 2011, 29:4442-4451.
38. Spencer H.L., Eastham A.M., Merry C.L.R., Southgate T.D., Perez-Campo F., Soncin F., Ritson S., Kemler R., Stern P.L., Ward C.M. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol. Biol. Cell 2007, 18:2838-2851.
39. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
40. Stern H.M., Padilla M., Wagner K., Amler L., Ashkenazi A. Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab. Clin. Cancer Res. 2010, 16:1587-1596.
41. Subbiah V., Brown R.E., Buryanek J., Trent J., Ashkenazi A., Herbst R., Kurzrock R. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol. Cancer Ther. 2012, 11:2541-2546.
42. Thiery J.P., Acloque H., Huang R.Y.J., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
43. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462.
44. van Raam B.J., Salvesen G.S. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim. Biophys. Acta 2012, 1824:113-122.
45. Vestweber D., Kemler R. Identification of a putative cell adhesion domain of uvomorulin. EMBO J. 1985, 4(13A):3393-3398.
46. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
47. Wei M.C., Zong W.X., Cheng E.H.Y., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
48. Wilson N.S., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat. Immunol. 2009, 10:348-355.
49. Wilson N.S., Yang B., Yang A., Loeser S., Marsters S., Lawrence D., Li Y., Pitti R., Totpal K., Yee S., et al. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011, 19:101-113.
50. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
51. Yang A., Wilson N.S., Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 2010, 22:837-844.
52. Yap A.S., Kovacs E.M. Direct cadherin-activated cell signaling: a view from the plasma membrane. J.Cell Biol. 2003, 160:11-16.